公开(公告)号：US20240294496A1

公开(公告)日：2024-09-05

申请号：US18292731

申请日：2022-08-29

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mitsuo NAGAI ,  Takashi FUKUYAMA ,  Yasuaki KAMADA ,  Jun NIIJIMA ,  Hirofumi KURODA ,  Yuki KAROJI ,  Keiichi MURAKAMI ,  Masayuki OMORI ,  Yusuke MIYASHITA ,  Atsushi KAMADA ,  Masaaki MATSUDA

IPC: C07D401/12 ,  C07C201/12 ,  C07C253/30 ,  C07D209/08

CPC classification number: C07D401/12 ,  C07C201/12 ,  C07C253/30 ,  C07D209/08

Abstract: The invention provides a production process allowing more high-yield and efficient synthesis of key intermediates (compound (2i) or a salt thereof, and compound (1g)) for production of E7090, which is useful as an FGFR inhibitor.

公开(公告)号：US20240294497A1

公开(公告)日：2024-09-05

申请号：US18292743

申请日：2022-08-29

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mitsuo NAGAI ,  Takashi FUKUYAMA ,  Yasuaki KAMADA ,  Jun NIIJIMA ,  Hirofumi KURODA ,  Keiichi MURAKAMI ,  Yuki KAROJI ,  Hiroyuki SAITO ,  Masayuki OMORI ,  Yusuke MIYASHITA ,  Atsushi KAMADA ,  Masaaki MATSUDA ,  Takanori KODERA

IPC: C07D401/14

CPC classification number: C07D401/14

Abstract: Provided is compound (3d) or a salt thereof, wherein the content of compound (IM-7) is 0.48 mass % or lower.

公开(公告)号：US20230074385A1

公开(公告)日：2023-03-09

申请号：US17757825

申请日：2020-12-21

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Kimihiro MATSUO ,  Taiju NAKAMURA ,  Yusuke MIYASHITA

IPC: A61K47/68 ,  A61K47/54

Abstract: Provided is a method of producing an antibody-drug conjugate represented by Formula I in the formula, Ab is an antibody or an antigen-binding fragment thereof, D is eribulin, m is an integer of 1 to 10, and p is an integer of 1 to 8, the method comprising: a step 1 of obtaining a compound represented by Formula (B) by reaction of eribulin or a salt thereof with a compound represented by Formula (A), in the formula, m is an integer of 1 to 10 and X is a phenoxy group or a nitrophenoxy group, and in the formula, n is an integer of 1 to 10, and a step 2 of obtaining the antibody-drug conjugate represented by Formula (I) by reaction of the compound represented by Formula (B) with Ab.